UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 OR 15(d) of
                       The Securities Exchange Act of 1934

                                February 24, 2005
                Date of Report (Date of earliest event reported)

--------------------------------------------------------------------------------
                                 ANTIGENICS INC
             (Exact name of registrant as specified in its charter)

-------------------------------------------------------------------------------
          DELAWARE                  000-29089             06-1562417
(State or other jurisdiction       (Commission          (IRS Employer
       of incorporation)           File Number)      Identification No.)

          630 Fifth Avenue, Suite 2100
             New York, NY 10111                                10111
     (Address of principal executive offices)                (Zip Code)

                                  212-994-8200
              (Registrant's telephone number, including area code)

--------------------------------------------------------------------------------

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))


Item 2.02         Results of Operations and Financial Condition

                  On February 24, 2005, Antigenics Inc. announced its financial
                  results for the quarter ended December 31, 2004. The full text
                  of the press release issued in connection with the
                  announcement is being furnished as Exhibit 99.1 to this
                  current report on Form 8-K.


Item 9.01         Financial Statements and Exhibits


         (c) Exhibits:

                  99.1     Press Release dated February 24, 2005

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                             ANTIGENICS INC.

Date: February 24, 2005
                                             By: /s/ Garo H. Armen
                                                 -----------------
                                               Garo H. Armen, Ph.D.
                               Chairman and Chief Executive Officer




EXHIBIT INDEX


The following designated exhibits are filed herewith:

Exhibits:

99.1                       Press Release dated February 24, 2005